Insulin-like growth factor-II
(Endocrinology 135: [1877] [1878] [1879] [1880] [1881] [1882] [1883] [1884] [1885] [1886] 1994) A LTHOUGH the biological roles of insulin-like growth factor-I (IGF-I) as both a hormone and a paracrine growth factor are becoming increasingly clearer (for review, see Refs. 1 and 2), no overall concept has emerged of the physiological function of IGF-II in growth and metabolism.
The role of IGF-II has widely been postulated to be a fetal growth-promoting hormone. The most direct evidence for this was provided by DeChiara et al. (3) , who inactivated the IGF-II gene in mice by gene targeting. The growth of fetuses lacking functional IGF-II expression was impaired, but postnatal growth paralleled that of control littermates, suggesting that IGF-II does not play a major role in postnatal growth. These studies also demonstrated that the mouse IGF-II gene is subject to genomic imprinting and that only the paternal allele is active (4). Furthermore, IGF-II is known to stimulate the growth and metabolism of preimplantation mouse embryos in vitro (5).
IGF-II messenger RNA (mRNA) expression is high in most fetal tissues and declines after birth, except in neural tissue (6) (7) (8) . Postnatal plasma levels of IGF-II are essentially low in rats and mice, but in other species, such as sheep and guinea pig, serum IGF-II levels decline somewhat after birth, but stay relatively high (2). In man, postnatal levels are even higher than prenatal levels; they increase with gestational age and rise during the first weeks of life, with no pubertal increase (9, 10). Postnatal IGF-II expression in man is driven by an alternative promoter, which starts after birth and confers IGF-II gene expression mainly in the liver (11, 12) .
Elevated IGF-II expression is found in a variety of malignancies in humans (for review, see Ref. 13) , in liver tumors of transgenic mice harboring the early region of simian virus-40 under the control of either human antithrombin-III regulatory sequences (14,15) or the major urinary protein (MUP) promoter (15), and in hepatic neoplasms in transgenic mice containing the pre-S/S region of hepatitis-B virus controlled by the mouse albumin promoter and enhancer (15) .
The failure to demonstrate clear roles for IGF-II in postnatal growth physiology and pathology invited the generation of an animal model with postnatally elevated IGF-II mRNA and protein. We, therefore, produced transgenic mice carrying fusion genes in which a human IGF-II complementary DNA (cDNA) is placed under the transcriptional control of the rat phosphoenolpyruvate carboxykinase (PEPCK) promoter. In this first study, we investigated the dietary regulation of PEPCK-IGF-II transgene expression and effects on IGF-I, IGF-binding proteins (IGFBPs), insulin, and glucose levels. Furthermore, we characterized the effects of elevated IGF-II on body and organ growth at 4 and 12 weeks of age. Serum sampling, hormone and IGFBP assays, and glucose determination Blood samples were taken by orbital puncture from mice under ether anesthesia;
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these were stored at 4 C for 30 min and centrifuged twice for 10 min each time at 15,000 X g to obtain serum. Fasting serum samples were taken after a 14-h food deprivation period. Serum samples were stored in loo-p1 aliquots at -20 C until further analysis. Serum concentrations of IGF-II, IGF-I, and IGFBP-2 were determined by RIA, as described previously (10, 22, 23 ations, matings of hemizygous transgenic mice with controls produced about 50% transgenic offspring. All transgenic mice investigated in this study were hemizygotes, and all controls were their nontransgenic littermates.
Expression of PEPCK-IGF-II gene constructs
Steady state levels of PEPCK-IGF-II mRNA expression were studied by Northern blot analysis of total RNA from a variety of organs. RNA from liver, kidney, and intestine, major sites of endogenous PEPCK expression (30, 31), were used to compare transgenic animals from both lines with controls. A transgene-specific RNA of about 1 kb was detected in organ samples from line 525-41 (Fig. 3A) . We, therefore, concentrated our further studies on this line and tested a wide spectrum of organs for PEPCK-IGF-II-specific -23
Liver (10 pg) Intestine (2 vg) Kidney (5 pg Endo. 1994 Vol. 135, No. 5 mRNA expression. In addition to liver and kidney, we detected a transgene-specific transcript in several parts of the gut (duodenum, jejunum, ileum, and colon, but not caecum). No PEPCK-IGF-II expression was found in adipose tissue (Fig. 3B) .
Serum IGF-II concentrations in transgenic mice belonging to line 525-41 were 2-to 3-fold higher than those in controls, with significantly greater IGF-II levels in male than in female mice (Fig. 4A) . Circulating IGF-II levels were not different between transgenic animals younger or older than 12 weeks (Fig. 4B) . After a 14-h fasting period, circulating IGF-II levels increased in transgenic mice (P < 0.05), but decreased in controls (P < O.Ol), suggesting correct nutritional control of the PEPCK promoter-driven transgene (Fig. 5) . 327.9 (7.4) and 362.0 (6.5), respectively (P < 0.001). Sexrelated differences in IGF-I levels were seen in both groups of mice. Transgenic males displayed significantly lower IGF-I levels than transgenic females, suggesting a negative relationship between IGF-I and IGF-II levels (Fig. 4A) . A negative correlation between IGF-II and IGF-I levels in PEPCK-IGF-II transgenic mice was also shown by linear regression analysis (Fig. 6A) . Serum IGF-I levels in male controls were significantly higher than those in control females (Fig. 4A ). An effect of age on serum IGF-I concentrations was seen in the control group in which animals younger than 12 weeks had significantly higher levels than older mice. Serum IGFBP-2 was significantly elevated in PEPCK-IGF-II transgenic mice, with a sex-related difference mirroring that observed with IGF-II (Fig. 4A) . In controls, IGFBP-2 levels in male and female mice were not significantly different. An effect of age was seen in both groups of mice investigated ( Fig. 4B ): animals younger than 12 weeks had significantly higher IGFBP-2 values than older animals.
Linear regression analysis revealed a significant positive correlation between serum IGF-II and IGFBP-2 levels as well as a significant negative correlation between serum IGF-I and IGFBP-2 in PEPCK-IGF-II transgenic mice (Fig. 6, B The graph shows the means and SDS. Serum IGFBP-2 in transgenic mice was significantly higher than that in controls (P < 0.01). Furthermore, transgenic mice tended to have elevated serum concentrations of IGFBP-3 (P = 0.0736) and IGFBP-4 (P = 0.0967).
Ligand blot analysis of serum from 12-week-old animals confirmed the difference in IGFBP-2 levels between transgenie mice and controls. Similarly, serum concentrations of IGFBP-3 and IGFBP-4 tended to be higher in transgenic mice than in controls (Fig. 7) .
Effects of fasting on IGF-I, IGFBP-2, insulin, and glucose levels These effects are summarized in Fig. 5 . After a 14-h fasting period, serum IGF-I levels were reduced in both groups of mice (P < O.Ol), but more markedly in transgenic mice than in controls, reflecting again the negative relationship between IGF-II and IGF-I.
IGFBP-2 was up-regulated by fasting in both groups of mice investigated, again more markedly in transgenic mice (70%; P C 0.001) than in controls (40%; P < 0.01).
Under ad libitum feeding, serum insulin concentrations were slightly, but not significantly, lower in transgenic mice than in controls, whereas 14-h food deprivation resulted in significantly reduced insulin levels in transgenic mice com- No 5 pared to controls. In contrast, fasting glucose levels were not significantly different between the two groups of mice.
Effects of elevated IGF-II on body and organ growth
Data obtained from 4-and 12-week-old PEPCK-IGF-II transgenic mice and controls are presented in Tables 1 and  2 . Although there were no significant differences between the groups, transgenic mice displayed slightly higher values for body weight, body dimensions, carcass weight, and abdominal fat at 4 weeks of age. In 12-week-old animals, all of these differences were absent (Table 1) .
Determination of organ weights (Table 2 ) revealed significantly greater kidney and testis weights for 4-week-old transgenic mice than for age-matched controls. The mean kidney weight of transgenic mice was also increased when related to body weight (6.5 X 10e3 VS. 6.1 X 10V3; P < 0.05). At 12 weeks of age, there were no significant differences in kidney or testis weight, but transgenic mice displayed significantly higher weights of the adrenal glands than controls (P < 0.05). The difference in mean relative adrenal weight (1.8 x 10e4 VS. 1.5 X 10e4) reached the borderline of statistical significance (P = 0.0551).
Discussion
The biological activities of IGFs in viva have been subject to extensive research. A number of studies (3,4, 32-34) used the gene targeting approach to generate mice deficient for IGF-II, IGF-I, IGF type 1 receptor, or combinations of these. Analysis of phenotypes resulting from the lack of IGFs and/ or their receptors provided a plethora of new aspects concerning their roles in prenatal and postnatal development. However, the evidence given is indirect, because conclusions are drawn from null mutants. Therefore, many studies on the biological function of IGF-II involved experimental designs with artificially increased local or circulating levels of IGF-II.
Exogenous application of IGFs allows only short studies and may cause immunological problems if heterologous proteins are used. Transplantation of IGF-II-secreting tumors into nude mice or rats (35,36) provides a model for prolonged studies. However, standardization of these experiments is difficult because tumor growth may be variable and can compromise the animals.
To overcome these problems, we generated transgenic mice expressing human IGF-II under the control of the PEPCK promoter. The gene coding for PEPCK (GTP; EC 4.1.1.32), a pace-setting enzyme in gluconeogenesis, is expressed in multiple tissues and regulated in a complex tissuespecific manner (37, 38). In the liver, CAMP, glucocorticoids, thyroid hormone, PRL, and retinoic acid are inducers, and insulin and diacylglycerol are inhibitors of expression (38). A bovine GH gene controlled by 460 bp of the rat PEPCK promoter was shown to follow the expression of the endogenous PEPCK gene with respect to both developmental pattern and tissue specificity. Expression started on day 19 of fetal development and increased about 200-fold after birth (39). Expression was detected in liver, kidney, intestine, adipose tissue, and mammary gland (30, 31). Starvation stimulated expression of the PEPCK promoter-regulated The table shows the LSMs and SES of LSMs calculated for both groups of mice investigated. Number of animals investigated per age class: 4 weeks, T, 4& 100; C, 13d, 69; 12 weeks: T, 118, 89, C, lld,8P.
LSMs of T and C mice were compared using Student's t tests; P values are shown in the fifth and eighth columns, respectively, and significant differences are indicated. a P < 0.001. Lung bg)
Spleen ( which was also seen in our study. As a consequence of PEPCK-IGF-II transgene expression, we observed a number of endocrine changes. A negative relationship between serum IGF-II and IGF-I levels in PEPCK-IGF-II transgenic mice might be due to displacement by IGF-II of IGF-I from IGFBPs, mainly IGFBP-3, which is the most abundant IGFBP in the circulation (40,41). IGFBP-3 was slightly, but not significantly, elevated in PEPCK-IGF-II transgenic mice. The IGF levels measured reflect almost exclusively IGF peptides bound to IGFBPs, as the half-lives of free IGFs in the circulation are very short (42). In contrast to PEPCK-IGF-II transgenic mice, circulating IGFBP-3 increased significantly in IGF-I transgenic mice in both the presence and absence of GH, suggesting that IGF-I, rather than GH, is the primary regulator of serum . Furthermore, a recent study showed elevated IGF-I and IGFBP-3 serum levels in transgenic mice with inducible ovine GH gene expression (44). However, this model is not suitable to separate the effects of IGF-I on circulating IGFBP-3 levels from those of GH.
to stimulate increases in serum IGFBP-2 (43). IGFBP-2 is the second most abundant IGFBP in the circulation and may act primarily as an IGF-II-BP, as its affinity for IGF-II is 1 order of magnitude higher than that for IGF-I (45). A comparison of mouse, rat, and human IGFBP-2 sequences revealed a high degree of homology among all three species (46). Although little is known so far about the regulation of IGFBP-2, a working hypothesis has emerged that IGFBP-2 is mainly regulated by its primary ligand, IGF-II (23). PEPCK-IGF-II transgenic mice show significantly elevated serum IGFBP-2, with a sex-related difference mirroring that observed with IGF-II. Furthermore, linear regression analysis revealed a significant positive correlation between IGF-II and IGFBP-2 levels in PEPCK-IGF-II transgenic mice, providing direct experimental evidence that IGF-II is a major regulator of IGFBP-2. The significant negative correlation between IGF-I and IGFBP-2 may primarily be due to the negative relationship between IGF-I and IGF-II. Although IGF-I is capable of increasing serum IGFBP-2 (43), up-regulation of IGFBP-2 obviously does not depend on an increase in serum IGF-I. Overexpression of IGF-I in transgenic mice was also found
The observation that in both groups of mice animals Endo. 1994 Vol135. No 5 younger than 12 weeks had significantly higher IGFBP-2 values than older animals is consistent with findings in humans, in which IGFBP-2 levels are high at birth, decline by late puberty, and increase again with aging (23). IGFBP-2 was up-regulated by fasting, which was also found in humans (23) and rats (47). The greater increase in IGFBP-2 levels in transgenic mice (70%) than in controls (40%) indicates a synergistic effect of elevated IGF-II and fasting on IGFBP-2 levels. Fasting insulin concentrations in serum from PEPCK-IGF-II transgenic mice were significantly lower than those in controls. A reduction of insulin levels is also found in patients suffering from nonislet cell tumor-induced hypoglycemia due to large tumors producing excessive amounts of IGF-II or its prohormone forms (48). In contrast to these patients, PEPCK-IGF-II transgenic mice are not hypoglycemic. This may be due to a difference in the absolute level of IGF-II produced or a difference in the relative amount of IGFBPs that could block the hypoglycemic action of excessive IGF-II. IGFBP-3 is low in nonislet cell tumor-induced hypoglycemia, and its increase after GH therapy results in alleviation of hypoglycemia (49). A study of the acute action of IGF-II on glucose metabolism in adult rats showed that compared to insulin, about 50 times higher doses of IGF-II were required to produce identical in vim responses (50). The hypothesis that the development of hypoglycemia as a consequence of elevated IGF-II may be dose dependent is supported by a recently published study on transgenic mice expressing IGF-II under the transcriptional control of the MUP promoter (51). A line of mice with a mean circulating IGF-II level of 454 rig/ml showed a 20% reduction in glucose levels throughout life; another transgenic line with an average serum IGF-II level of 243 rig/ml developed hypoglycemia with increasing age. Furthermore, a large reduction in body fat was observed in both of these lines, but the mechanism for this metabolic effect of IGF-II is still unclear. Our estimations of the body compositions of 4-and 12-week-old PEPCK-IGF-II transgenic mice did not suggest a significant reduction in body fat.
In addition to a number of endocrine consequences, elevated IGF-II in transgenic mice had subtle effects on the growth of several organs, which can at least in part be explained by findings of other studies. The roles of different growth factors, including IGFs, in kidney development have recently been reviewed by Hammerman et al. (52) . IGF-II is expressed in human fetal kidney, mainly in undifferentiated stromal and blastemal cells (53). Furthermore, IGF-I and IGF-II are required for the growth and development of rat metanephroi in vitro (54). In vim, compensatory renal growth after unilateral nephrectomy in immature, but not adult, rats was associated with increased renal IGF-I gene expression and enhanced specific renal binding of IGF-I and IGF-II to plasma membranes (55). In another study, elevated IGF-II levels were found in kidney tissue and serum of immature, but not adult, rats during compensatory kidney growth after uninephrectomy (56). Conversely, kidney weight was increased in nude mice transplanted with pieces of IGF-IIsecreting Wilms' tumors (36). As nephrogenesis of mice is not completed with birth (57) and PEPCK promoter-driven IGF-II expression in the kidney starts around birth, there is a common window for both phenomena that could explain the slightly, but significantly, increased kidney weight of PEPCK-IGF-II transgenic mice at the age of 4 weeks. Complex stereological investigations will be necessary to determine the organ structures undergoing increased growth and to clarify why the difference in kidney weight is decreased at the age of 12 weeks.
The effects of IGF-II on the adrenal gland are also well known. Quantitation and localization of IGF-II mRNA in the developing ovine adrenal gland provided evidence for an autocrine/paracrine role of . In vitro studies on fetal rat (59) or human adrenal cells (60) demonstrated a proliferative effect of IGF-II. Furthermore, IGF-II, more potently than IGF-I, stimulated bovine adrenocortical steroidogenesis through the IGF type 1 receptor (61).
Although we observed distinct effects of IGF-II overexpression on organ growth in transgenic mice, they were relatively small compared to those in transgenic mice expressing human IGF-I (62-64) or GHs from different species (for review, see Ref. 65 ). These studies demonstrated that the growth-promoting actions of GH are in large part mediated by IGF-I, but also suggested that GH and IGF-I act independently in specific tissues; GH appears to stimulate liver growth directly, whereas IGF-I has a specific GH-independent effect on brain growth (for review, see Ref. 66 ).
The lack of major changes in body and organ growth of PEPCK-IGF-II transgenic mice may be due to relatively high levels of IGF-I persisting in these animals. The growth effects of IGF-II are probably mediated via the IGF type 1 receptor, which usually binds IGF-I with higher affinity than IGF-II (for review, see Ref. 67) .
A synthesis of our results and findings of studies on mice expressing IGF-II transgenes with different tissue specificities [part only available in abstract form (68-70)] will further specify the endocrine and auto-/paracrine effects of IGF-II. Specifically, it will be interesting to determine whether aging PEPCK-IGF-II transgenic mice develop tumors with increased frequency, as has been observed in MUP-IGF-II transgenic mice (51). 
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